Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: DaiS who wrote (9487)	6/10/1998 7:02:00 PM
From: Gene Voss	Read Replies (1) \| Respond to of 23519

I can't see why everyone is so concerned over these 16 deaths.All these men would have died eventually plus the FDA has assured us Viagra was not implicated. With life threatening illnesses like this you have to expect some degree of risk.I don't imagine the families of these patients will discuss the temporal association between Viagra dosing and the death of their relatives with their attorneys.Since the FDA is unconcerned it must be totally safe. GV

To: DaiS who wrote (9487)	6/10/1998 7:03:00 PM
From: DaiS	Read Replies (1) \| Respond to of 23519

I mean apply the alprostadil to the urethra. Also bad to rub muse pellets on the outside of the penis, this is a waste.

To: DaiS who wrote (9487)	6/10/1998 9:12:00 PM
From: Sal Milani	Read Replies (2) \| Respond to of 23519

Dais - Your model seems reasonable although I have not tried to verify it. In some cases however, K=0; i.e., the MD will want to see the patient after every pack. As you say, the result is very dependent on the assumptions. If you use the value I had in my post 9467 of .4, we get the following number of MUSE scripts assuming there were 280,000 Viagra scripts: Muse scripts = 280000(1-.7).5*.4 = 16,800 per week. This is about the value of the MUSE total scripts before Viagra. This is what others on this thread have been expecting. Sal